Insiders Buy the Holdings of FYX ETF

A look at the weighted underlying holdings of the First Trust Small Cap Core AlphaDEX Fund (FYX) shows an impressive 10.2% of holdings on a weighted basis have experienced insider buying within the past six months.

START SLIDESHOW:
10 ETFs With Stocks That Insiders Are Buying »

EZCORP, Inc. ( EZPW), which makes up 0.40% of the First Trust Small Cap Core AlphaDEX Fund (FYX), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $2,196,351 worth of EZPW, making it the #30 largest holding. The table below details the recent insider buying activity observed at EZPW:

EZPW — last trade: $11.55 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
01/31/2014 Paul Rothamel President & CEO 13,250 $11.15 $147,683.41
01/31/2014 Mark Edward Kuchenrither Executive Vice President & CFO 1,000 $11.18 $11,180.00

And Methode Electronics, Inc. ( MEI), the #169 largest holding among components of the First Trust Small Cap Core AlphaDEX Fund (FYX), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $1,442,195 worth of MEI, which represents approximately 0.26% of the ETF's total assets at last check. The recent insider buying activity observed at MEI is detailed in the table below:

MEI — last trade: $38.21 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
03/18/2014 Paul G. Shelton Director 3,000 $30.14 $90,420.00
03/18/2014 Walter J. Aspatore Director 1,000 $29.97 $29,970.00

More from Stocks

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Why Spotify Is the Ultimate Speculative Stock to Buy

Why Spotify Is the Ultimate Speculative Stock to Buy

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data